• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study
【2h】

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study

机译：日常实践中，FIGO IIIC期至IV期卵巢癌，输卵管癌和腹膜癌患者的最大细胞减少：一项法国多中心回顾性研究

页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: To evaluate the outcome of maximal cytoreductive surgery in patients with stage IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and disease-free survival (DFS). Materials and Methods: Five hundred twenty-seven patients with stage IIIC (peritoneal) and stage IV (pleural) ovarian, fallopian tube, and peritoneal carcinoma underwent surgery between January 2003 and December 2007 in 7 gynecologic oncology centers in France. Patients undergoing primary and interval debulking surgery were included, whichever the number of chemotherapy cycles. The extent of disease, type of surgical procedure, and amount of residual disease were recorded. A multivariate analysis of the outcome was performed, taking into account the stage, grade, and timing of surgery. Results: Median DFS was 17.9 months, but median OS was not reached at the time of analysis. Complete cytoreductive surgery, without evident residual tumor at the end of the procedure, was obtained in 71% of all patients (primary surgery, 33%). After neoadjuvant therapy, the rate of complete debulking surgery was higher (74%) compared to primary cytoreductive surgery (65%). Twenty-three percent of patients needed 'ultra radical surgery' to achieve this goal. The most significant predictive factor for DFS and OS was complete cytoreductive surgery compared to any amount, even minimal (1Y10mm), of residual disease. In the group of patients with complete cytoreductive surgery, the patients undergoing surgery before chemotherapy showed better DFS than those having first chemotherapy. Conclusion: The findings confirm that complete cytoreduction is the criterion standard of surgery in the management of advanced ovarian, peritoneal, and fallopian tube cancer, whatever the timing of surgery. With experienced teams, surgery was completed, without evident residual tumor in 71% of the cases. © 2012 by IGCS and ESGO.
机译：目的：就总生存期（OS）和无病生存期（DFS）评估IIIC期至IV期卵巢癌，输卵管癌和腹膜癌患者最大程度的细胞减灭术的结果。材料与方法：2003年1月至2007年12月间，法国的7个妇科肿瘤中心对357例IIIC期（腹膜）和IV期（胸膜）卵巢，输卵管和腹膜癌患者进行了手术。无论化疗周期的多少，均包括接受初级和间歇性大剂量手术的患者。记录疾病的程度，手术方法的类型和残留疾病的数量。考虑到手术的阶段，等级和时机，对结果进行了多变量分析。结果：DFS中位数为17.9个月，但在分析时未达到中位OS。在所有患者中，有71％的患者完成了完整的细胞减灭术，没有明显的残留肿瘤（初次手术，占33％）。新辅助治疗后，完全减瘤手术的比率（74％）高于原发性细胞减少手术（65％）。 23％的患者需要“超彻底手术”才能达到此目标。 DFS和OS的最重要预测因素是完整的细胞减灭术，与任何数量的残留疾病（甚至最小（1Y10mm））相比。在完成细胞减灭术的患者组中，化疗前接受手术的患者的DFS优于初次化疗的患者。结论：研究结果证实，无论手术时间如何，完全的细胞减少是晚期卵巢癌，腹膜癌和输卵管癌治疗的标准手术标准。在经验丰富的团队中，手术已经完成，在71％的病例中没有明显的残留肿瘤。 ©2012，IGCS和ESGO。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号